Background: Long-acting injectable (LAI) antipsychotic medications provide a potential solution to the poor adherence to oral therapies in schizophrenia. However, not all patients with schizophrenia seem to have therapeutic benefits using LAI antipsychotics. The objectives of this study were to investigate clinical factors in patients with schizophrenia who have continued the LAI antipsychotics compared with the patients who have discontinued the LAI antipsychotics. Methods: Data were collected by retrospective chart review of all 150 patients prescribing LAI therapy during 2005-2012 in a mental hospital. The data including age at onset, age at starting LAI antipsychotics, duration of illness at starting LAI antipsychotics, total number of admission before starting LAI antipsychotics were gathered. The subjects were classified into three group; 1) the continuation group (n=27, 18.0%), 2) the discontinuation group (n=57, 38.0%), and 3) the follow-up loss group (n=66, 44%). The ANOVA were used to compare the clinical variables among 3 groups. The stepwise multiple linear regression analyses were conducted to evaluate the association between the duration of LAI medications and clinical variables. Results: There were significant differences among three groups in age (52.9 ± 9.1, 44.8 ± 12.9, 49.5 ± 12.0, p=0.009), age at onset (30.7 ± 10.4, 24.6 ± 9.9, 26.2 ± 8.6, p=0.027) and age at starting LAI medications (44.1 ± 8.9, 37.0 ± 12.4, 40.8 ± 11.2, p=0.021). In regression analyses, the duration of LAI medications were significantly associated with age (β=1.727, p<0.001), age at starting LAI medications (β=-1.489, p<0.001), and the total number of admission before starting LAI medications (β=-0.177, p=0.008). Discussion: The continuation of LAI medications was associated with age, age at starting LAI medications and the number of admission before starting LAI medications.
Background: The high prevalence of obesity in patients suffering from psychosis is a major concern as it dramatically increases the mortality rates of such patients in the long term. The mechanisms by which these patients develop overweight are poorly understood. It has been suggested that exposure to Childhood Trauma (CT) may play a role in the risk for obesity; however, whether this is the case for Early Psychosis (EP) patients and independently of the impact of medication has yet to be investigated. In addition, it is unknown whether the age at the time of exposure to CT can modulate the link between CT and obesity in EP patients. Methods: 136 EP patients aged 18-35 were recruited from the Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne). Body Mass Index (BMI), Weight Gain (WG) and Waist Circumference (WC) were measured and monitored prospectively after psychotropic prescription during a follow-up period of 1 year (patients were assessed at baseline, after 1, 2, 3, 6 months and 1 year of antipsychotic treatment). Patients were classified into Early-Trauma if they had faced at least one experience of abuse (physical, sexual, or emotional) or neglect (physical or emotional) before age 12, and Late-Trauma if the exposure had occurred between ages 12 and 16. Linear Mixed effect models with a random intercept were used to investigate the impact of Trauma (early or late) on the metabolic parameters longitudinally, Marko Chain Monte Carlo (MCMC) method was used to adjust these models with sufficiently large number of MCMC iterations. Models were adjusted for age, socioeconomic status, baseline BMI, medication intake prior to the first assessment and during the treatment phase, and by the diagnosis of depression. Results: Patients were more likely to have a diagnosis of Schizophrenia (61%; N=83), they had a mean age of 26 at the time of first assessment, and exposure to 1 or more forms of traumatic experiences before 16 years of age was present in 32% of the sample. No differences between groups were found at baseline in terms of BMI or WC. Late-Trauma patients, when compared to Non-Trauma patients showed greater WCs during the follow-up (p=0.012). No differences between Early or Late-Trauma patients and Non-Trauma patients were found in any of the other outcome measures during the follow up. Baseline BMI and treatment duration were significantly associated with the level of BMI and WC during the follow up. None of the other potential confounding factors were significantly associated with the outcome measures during the follow up. Discussion: Exposition to trauma during adolescence in EP patients is associated with a higher risk of greater WC during the early phase of the disease, independently of the medication intake, depression and other confounding factors. Specific preventive measures should be addressed in these patients in order to reduce the risk of obesity. Depending on the timing of traumatic exposure, different developmental mechanisms may underlie this differential possible impact on WC. Further studies on interactions between central consequences of traumatism and metabolic syndrome are warranted. Background: Paliperidone palmitate is a 2nd generation long-acting injectable (LAI) antipsychotic which is increasingly prescribed for patients with chronic schizophrenia. However, it is more expensive than 1st generation LAI antipsychotics and little is known about its effectiveness in a real world clinical setting. We sought to address this issue by analyzing a large electronic case register of patients with schizophrenia treated with LAI antipsychotics. Methods: Data were obtained from 1,281 patients in the South London and Maudsley NHS Foundation Trust (SLaM) Biomedical Research Centre (BRC) Case Register who were treated with an LAI antipsychotic between 1st April 2011 and 31st January 2015. The number of days spent as a psychiatric inpatient and the number of admissions to a psychiatric hospital were extracted using the Clinical Record Interactive Search tool (CRIS) and analyzed in each of the 3 years before and after LAI prescription using multivariable regression. Results: Patients who received paliperidone palmitate (n=430; 33.6%) spent more time in hospital (β coefficient 12.3 days, 95% CI 2.3 to 19.2, p=0.001) and were admitted to hospital more frequently (IRR 1.44, 95% CI 1.29 to 1.61, p<0.001) in the year prior to treatment than those treated with other LAI antipsychotics (n=851, 66.4%). However, there were no significant differences between paliperidone and the other LAI antipsychotics in the 3 years after initiation with respect to the number of days spent in hospital (β coefficient 5.4 days, 95% CI -57.3 to 68.2, p=0.86) or frequency of hospital admissions (Incidence rate ratio 1.07, 95% CI 0.62 to 1.83, p=0.82). Discussion: Paliperidone palmitate was more likely to be prescribed in patients with more severe illness, as indicated by a history of more frequent and lengthy hospital admissions prior to initiation. The absence of differences in outcomes after initiation indicates that the effectiveness of paliperidone palmitate was similar to that of other LAI antipsychotics. However, paliperidone palmitate may be better tolerated than other 1st generation LAI antipsychotics with a lower rate of discontinuation. These findings merit consideration in relation to the high cost of paliperidone palmitate compared to other LAI antipsychotics. 
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Background: The dopamine hypothesis of schizophrenia has been extensively proposed as a neurobiological mechanism that explains the relationship between schizophrenic symptoms and hyperdopaminergic states. This hypothesis is supported by direct and indirect evidence, and it mainly postulates that antipsychotics act blocking dopamine receptors. When focusing on delusional disorder patients, especially delusional disorder somatic type, a great effort towards the search for a biological basis of treatment response has been recently demonstrated. Thus, the main goal of this systematic review was to examine the evidence explaining the biological underpinnings of treatment response in delusional disorder. Methods: A systematic review was performed using Pubmed, Scopus and PsycINFO databases (from 1990 to October 2017), according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The following search terms were used: [('treat*' OR 'therap*' OR 'biol*') AND ('delusional disorder')]. This systematic computerized search was completed by additional studies hand-checked through reference lists from the included studies and review articles. Studies were only included if the met our inclusion criteria: (a) the International Classification of Diseases (ICD) or Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnosis for delusional disorder, (b) be published in peer-reviewed journals, (c) in English, German or Spanish, (d) and reporting a hypothesis for the biological basis of treatment response in delusional disorder, irrespective of method and study design. Exclusion criteria were: (a) studies including organic delusional disorder or (b) somatic delusions secondary to other psychiatric diagnoses. The literature search strategy, data extraction and synthesis was conducted independently by two authors (A.G.R, F.E.). When disagreement, it was solved by consensus. Results: A total of 59 articles were identified, of which 12 met our inclusion criteria. Four hypotheses were addressed: (1) Dopaminergic dysfunction (n=4): ziprasidone-induced supersensitivity psychosis by chronic blockade of D2 Dopamine Receptor (DRD2) (n=1); pretreatment levels of plasma homovallinic acid (pHVA) (n=1); dopamine transporter (DAT) dysfunction (n=1) and effectiveness of aripiprazole (DRD2 agonist) (n=1). (2) Serotonergic dysfunction (n=6): drug occupancy in 5-HT1A and 5-HT2A receptors (n=3) and efficacy of 5-HT2 antagonists (n=3). Brain dysfunction (n=7): hypoperfusion in cerebral blood flow in temporal and parietal lobes, left side (n=5), right side (n=1) and lack of basal ganglia and subcortical gray matter lesions (n=1). Genetic evidence (n=1): implications of DRD2 Ser311Cys, DRD3 Ser9Gly and TH VNTR polymorphisms. Discussion: The strongests biological contributors for treatment response in delusional disorder seem to be those implicating monoaminergic systems, particularly dopamine and serotonergic neurotransmitters. Although the low level of evidence, the serotonergic dysfunction may be associated with response rates, especially in delusional disorder somatic type. Background: Negative symptoms of schizophrenia are key predictors of long-term disability. It is important to understand whether treatment with long-acting injectable antipsychotics can improve negative symptom psychopathology. Paliperidone palmitate 3-month formulation (PP3M) provides a sustained release of paliperidone, permitting a significantly extended dosing interval of only 4 doses per year in patients with schizophrenia. The efficacy of PP3M as assessed by relapse rate is comparable to the paliperidone palmitate 1-month formulation (PP1M). The purpose of this post-hoc analysis was to compare the improvement in negative symptoms in patients treated with PP1M and PP3M. Methods: Data from a randomized, double-blind (DB), parallel-group, multicenter, phase 3 study in patients with schizophrenia were analyzed. Patients aged 18 to 70 years with schizophrenia (DSM-IV-TR) and a total Positive and Negative Syndrome Scale (PANSS) score of 70-120 at screening were enrolled. After screening (3 weeks), patients entered a 17-week open-label (OL) phase, to receive PP1M (day 1 [150 mg eq. deltoid], day 8 [100 mg eq. deltoid], weeks 5, 9 and 13 [50, 75, 100, or 150 mg eq., deltoid/ gluteal]) and entered a 48-week DB phase and were randomized (1:1) to receive fixed doses of either PP1M (50, 75, 100, or 150 mg eq., stabilized in OL) or PP3M (175, 263, 350, or 525 mg eq.) in deltoid or gluteal muscle until they relapsed or withdrew from study. The PANSS total scores with emphasis on 7-item negative subscale scores for PP1M vs PP3M were assessed. Results: Of 1429 patients enrolled, 1016 were randomized to receive PP3M (n=504) or PP1M (n=512) in DB phase. Majority of patients were men and white (both 55%), with a mean (SD) age of 38.4 (11.86) years. At baseline, the mean (SE) negative subscale total was 23.2 (0.12), indicating a moderate to severe level of negative symptoms. Negative subscale and negative symptoms factor scores showed continuous improvements throughout the OL and double-blind phases of the study -mean (SD) at OL baseline and DB endpoint for total negative subscale score and symptom factor score were 23.2 (4.60) and 22.3 (4.87), and 15.9 (4.99) and 14.9 (4.81), both R2:0.16, respectively. The mean (SD) PANSS negative subscale score changes from DB baseline for PP1M vs PP3M were similar over time (mean change from baseline to DB endpoint was -1.4 (3.67), R2:0.06 vs -1.4 (3.63), R2:0.05). Discussion: Development of an LAI antipsychotic with less frequent dosing than those currently available would be of potential advantage to patients, caregivers, and prescribers. PP3M and PP1M demonstrated consistent and similar efficacy in patients with moderate to severe negative symptoms of schizophrenia over the observed timepoints, including impact on patients with predominantly negative symptoms. Longer continuous treatment with PP3M showed greater benefit. This indicates that long-acting therapies are associated with continued improvement in negative symptoms over time. Treatment with LAIs for longer than a year was associated with the greatest improvements in negative symptoms.
